SEC Form 4 · accession 0000891293-18-000088
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce J. Seeley
Officer — EVP, Chief Operating Officer
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $1.88 | Sep 18, 2018 | A | 125,000 | A | — | Sep 18, 2028 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019.